Search 

Xcovery Vision is developing small molecule kinase inhibitors for opthamology indications. We have 4-5 canidates licensed exclusively to Xcovery Vision from Xcovery for the purpose of developing drugs for several eye diseases.

We are a spin out of Xcovery the parent oncology company founded by Sheridan Snyder founder of Genzyme and Dr. Chris Liang developer of Sutent, Pfizer's leading kidney cancer drug.

We are developing a oral drug for AMD which will be going into a Phase 1B trial this October. 

Please visit our website for more information www.xcoveryvision.com

Zosano Pharma (ZP), a spin-off of J&J, offers a fully-developed and validated transdermal drug-delivery platform to deliver small molecules, peptides, proteins and vaccines on a band-aid like patch with the efficacy of injectables.

Totally pain-free, the ZP patch offers quick onset of action, delivers with the efficacy of an injection and is stable at room temperature. It has been successfully tested with 30 compounds. The most advanced product is PTH for severe osteoporosis with completed Ph2 studies. Rights to PTH for select Asian countries have been granted to Asahi-Kasei Pharma, Japan.

ZP products are produced in its own GMP manufacturing facility at a low cost and offer attractive margins versus currently-marketed injectables.

ZP products are attractive to patients (pain-free & don't require refrigeration), payors (priced competitively versus marketed products) and pharma companies (for life cycle extension with ZP IP extending to 2027).